Abridge Announces Strategic Partnerships with Nvidia and Eli Lilly to Expand AI Healthcare Platform
Medical AI startup Abridge unveiled a new clinician intelligence platform alongside strategic partnerships with Nvidia and Eli Lilly at a New York event on Thursday. The company, valued at $5.3 billion after a recent $316 million funding round, is expanding beyond clinical note-taking into billing, clinical decision support, and pharmaceutical trial screening. The moves position Abridge as a potential infrastructure layer connecting providers, payers, and life sciences companies through real-time doctor-patient conversation data.
Abridge, the AI healthcare startup cofounded by Dr. Shiv Rao in 2018, announced a broad platform expansion at a midtown Manhattan event, including a co-development agreement with Nvidia to build what the companies describe as the first foundation model purpose-built for clinical conversations—distinct from general large language models adapted for medicine. Eli Lilly also made a strategic investment in Abridge, with an initial focus on using the platform's ability to surface clinical trial eligibility directly from within patient-clinician conversations to accelerate pharmaceutical trial enrollment. The company reports its platform is live at more than 300 health systems, including Northwestern Medicine, Emory Healthcare, and Johns Hopkins, supporting over 100 million clinical conversations annually and serving more than 250 million patients. Abridge has raised approximately $1.1 billion to date, closing a $316 million Series E extension in April 2026 at a $5.3 billion valuation, with Nvidia's venture arm NVentures among its backers. The platform now captures real-time patient-clinician dialogue and automatically generates clinical notes, billing codes, and patient summaries, with new capabilities added before, during, and after the clinical encounter. The ambient clinical intelligence market Abridge is targeting was valued at $7.24 billion in 2025 and is projected to reach $56.61 billion by 2035, with Microsoft—which acquired Nuance for $19.7 billion in 2022—as the dominant incumbent and several well-funded challengers. Analysts expect the field to consolidate within 12 to 18 months, raising questions about whether Abridge's expansion into payments and life sciences creates a defensible competitive advantage.
What's missing
Independent clinical validation data for Abridge's expanded platform capabilities—particularly for AI-generated billing codes and clinical decision support—is absent from all sources. The specific financial terms of the Eli Lilly strategic investment were not disclosed. Additionally, the regulatory pathway and FDA oversight status for AI-generated clinical orders and billing codes, which carry direct patient safety and financial implications, is not addressed.
How coverage differed
Fortune provided extensive detail on Abridge's business model ambitions, competitive landscape, and governance risks, framing the story around whether the company can become 'the operating system for medicine.' The Wall Street Journal and STAT News treated the Nvidia partnership as the primary news hook, with STAT emphasizing the competitive market context and the billboard nature of the announcements.
What different sources said
- STAT NewsCenter
STAT+: Abridge inks deals with Nvidia and Lilly
- FortuneCenter
Abridge wants to be the operating system for medicine—and NVIDIA and Eli Lilly are helping build it
- The Wall Street JournalCenter
Exclusive | Nvidia Is Developing an AI Healthcare Model With Startup Abridge
Related
Chicago Woman's Five-Year Symptom Journey Leads to Rare Brain Tumor Diagnosis
Melony Aponte, 26, was diagnosed with a 4.5-centimeter acoustic neuroma after five years of symptoms she attributed to stress, COVID-19, and aging. The rare, noncancerous tumor—affecting roughly one in 100,000 people—had grown large enough to compress her hearing and balance nerve before it was identified via MRI in March 2025. Her case highlights how acoustic neuroma symptoms can mimic common conditions, potentially delaying diagnosis for years.
Study Finds Aging Shifts Walking Strategy Toward Stability at the Cost of Efficiency
A new study from Flinders University and the University of Canberra found that as people age, their bodies adopt a 'safety-first' walking pattern that prioritizes balance over efficient movement. Researchers analyzed gait data from 107 healthy adults aged 26 to 86, identifying increased ankle muscle co-contraction and reduced push-off power as key age-related changes. The findings suggest that fall prevention programs should target balance and coordination, not just muscle strength.
Tick Populations Surge in Urban Areas Across Northeast
Experts across the northeastern United States and Canada are warning of an unusually early and widespread tick season, with disease-carrying ticks increasingly found in urban parks and green spaces. Lyme disease cases in Canada reached a record 7,105 in 2025, up from 5,809 the previous year, while U.S. cities including Philadelphia, Pittsburgh, Washington D.C., and New York are reporting rising tick activity. The expansion poses a public health challenge because urban residents are less likely to take tick-bite precautions than those in rural areas.